HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Who May Qualify: - Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD) - Enroll HD participant - Capable of consenting or have a legal representative (parent/guardian for juveniles) - Capable of complying with study procedures - All participants other than family and community controls must have had a genetic test for HD Who Should NOT Join This Trial: - Drug trial within 30 days of any sampling visit - Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days) - Antiplatelet or anticoagulant therapy within 14 days - Significant comorbidity - Needle phobia, headache, spinal surgery / deformity - Clotting or bruising disorder - Screening blood test abnormalities \>10% outside normal range - Drug / alcohol abuse - Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential - Predictable non compliance or unwillingness - Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days Always talk to your doctor about whether this trial is right for you.